These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 14501983)

  • 1. Cost-effectiveness of drotrecogin alfa (activated).
    Tsitanidis J
    Crit Care Med; 2003 Sep; 31(9):2414-5; author reply 2415. PubMed ID: 14501983
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.
    Angus DC; Linde-Zwirble WT; Clermont G; Ball DE; Basson BR; Ely EW; Laterre PF; Vincent JL; Bernard G; van Hout B;
    Crit Care Med; 2003 Jan; 31(1):1-11. PubMed ID: 12544986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
    Davies A; Ridley S; Hutton J; Chinn C; Barber B; Angus DC
    Anaesthesia; 2005 Feb; 60(2):155-62. PubMed ID: 15644013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost-effectiveness of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain].
    Sacristán JA; Prieto L; Huete T; Artigas A; Badia X; Chinn C; Hudson P
    Gac Sanit; 2004; 18(1):50-7. PubMed ID: 14980173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drotrecogin alfa (activated) in South African private hospital ICUs.
    Hodgson RE; Williams PG; Foden AP; Grolman D
    S Afr Med J; 2003 Jul; 93(7):474-5. PubMed ID: 12939910
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany.
    Neilson AR; Burchardi H; Chinn C; Clouth J; Schneider H; Angus D
    J Crit Care; 2003 Dec; 18(4):217-27. PubMed ID: 14691895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term cost effectiveness of drotrecogin alfa (activated): an unanswered question.
    Banks SM; Gerstenberger E; Eichacker PQ; Natanson C
    Crit Care Med; 2003 Jan; 31(1):308-9. PubMed ID: 12545035
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of drotrecogin alfa (activated) on resource use and implications for reimbursement.
    Dasta JF; Cooper LM
    Pharmacotherapy; 2002 Dec; 22(12 Pt 2):216S-222S. PubMed ID: 12492228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated).
    McEvoy M
    Am J Crit Care; 2003 Sep; 12(5):398; author reply 398. PubMed ID: 14503421
    [No Abstract]   [Full Text] [Related]  

  • 10. Management challenge with drotrecogin alfa (activated).
    Vanscoy GJ
    Am J Health Syst Pharm; 2002 Feb; 59 Suppl 1():S23-9. PubMed ID: 11885411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence-based disease management in medication-use evaluation: application to drotrecogin alfa (activated) in severe sepsis.
    Durthaler JM; Ernst FR
    Am J Health Syst Pharm; 2006 Aug; 63(15):1453-60. PubMed ID: 16849712
    [No Abstract]   [Full Text] [Related]  

  • 12. Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated).
    Morris PE
    Am J Crit Care; 2003 Mar; 12(2):94-7. PubMed ID: 12625165
    [No Abstract]   [Full Text] [Related]  

  • 13. Appraisal of treatment for severe sepsis in intensive care units.
    Burchell M; Ruiz F; Barnett D
    Ann R Coll Surg Engl; 2005 Jul; 87(4):283-4. PubMed ID: 16888847
    [No Abstract]   [Full Text] [Related]  

  • 14. Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.
    Frampton JE; Foster RH
    Pharmacoeconomics; 2004; 22(7):445-76. PubMed ID: 15137883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drotrecogin alfa (activated) for severe sepsis.
    Drug Ther Bull; 2006 Jan; 44(1):5-8. PubMed ID: 16425899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures.
    Betancourt M; McKinnon PS; Massanari RM; Kanji S; Bach D; Devlin JW
    Pharmacoeconomics; 2003; 21(18):1331-40. PubMed ID: 14750900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
    Green C; Dinnes J; Takeda AL; Cuthbertson BH
    Int J Technol Assess Health Care; 2006; 22(1):90-100. PubMed ID: 16673685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Medical-economic evaluation of severe sepsis].
    Guidet B
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():28-30. PubMed ID: 15359937
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis.
    Fowler RA; Hill-Popper M; Stasinos J; Petrou C; Sanders GD; Garber AM
    J Crit Care; 2003 Sep; 18(3):181-91; discussion 191-4. PubMed ID: 14595571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drotrecogin alfa's impact on intensive care workload in real life practice: a propensity score approach.
    Riou França L; Payet S; Le Lay K; Launois R
    Value Health; 2008 Dec; 11(7):1051-60. PubMed ID: 18494757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.